Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy
Year: 2014
Type: article
Abstract: Diabetes is affecting the life of millions of people. A large proportion of diabetic patients suffer from severe complications such as neuropathic pain, and current treatments for these complications have deleterious side effects. Thus, alternate therapeutic strategies are needed. Recently, the elevation of epoxy-fatty acids through inhibition of soluble epoxide hydrolase (sEH) was shown to reduce diabetic neuropathic pain in rodents. In this report, we describe a series of newly synthesized sEH inhibitors with at least 5-fold higher potency and doubled residence time inside both the human and rodent sEH enzyme than previously reported inhibitors. These inhibitors also have better physical properties and optimized pharmacokinetic profiles. The optimized inhibitor selected from this new series displayed improved efficacy of almost 10-fold in relieving pain perception in diabetic neuropathic rats as compared to the approved drug, gabapentin, and previously published sEH inhibitors. Therefore, these new sEH inhibitors could be an attractive alternative to treat diabetic neuropathy in humans.
Source: Journal of Medicinal Chemistry
DOI: 10.1021/jm500694p
Authors: Kin Sing Stephen Lee, Jun-Yan Liu, Karen M. Wagner, Svetlana Pakhomova, Hua Dong, Christophe Morisseau, Samuel H. Fu, Jun Yang, Peng Wang, Arzu Ulu, Christina A. Mate, Long V. Nguyen, Sung Hee Hwang, Matthew L. Edin, Alexandria A. Mara, Heike Wulff, Marcia E. Newcomer, Darryl C. Zeldin, Bruce D. Hammock
Language: English
Subfield: Biochemistry
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Funders: National Science Foundation, U.S. Department of Energy, American Asthma Foundation, National Institutes of Health, Office of Science, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Environmental Health Sciences, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Center for Research Resources, Division of Biological Infrastructure, Argonne National Laboratory
Awards: G102163711, G107546177, G1664757510, Biomarkers of Exposure to Hazardous Substances, G2287611682, G262962599, G3075337988, G3705839322, G3867968617, Novel Anticonvulsant and Neuroprotective Therapies for TETS and OP Intoxication, Role of Epoxygenated Fatty Acids in Modulating Pain, An Undulator Resource for Structural Biology, Gulf Coast Protein Crystallography Beamline (Development by Consortium), Hydrolytic enzymes in the metabolism of toxins, G6918803902, G7535657958, The Structural Basis for Control of 5-Lipoxgenease Activity, NE-CAT Center for Advanced Macromolecular Crystallography, G9000158641, Advanced Training in Environmental Health Sciences, G993149817
OpenAlex ID: W2327787157
